Good syndrome and other causes of cytomegalovirus retinitis in HIV-negative patients—case report and comprehensive review of the literature

Kenneth M. Downes¹*, Dariusz Tarasewicz², Laurie J. Weisberg³ and Emmett T. Cunningham Jr¹,4,5,6

Abstract

We describe a 65-year-old Thai woman who developed cytomegalovirus retinitis (CMVR) in the setting of Good syndrome—a rare, acquired partial immune deficiency caused by thymoma. The patient subsequently developed vitritis with cystoid macular edema (CME) similar to immune recovery uveitis (IRU) despite control of the retinitis with antiviral agents. A comprehensive review of the literature through December, 2014, identified an additional 279 eyes of 208 patients with CMVR in the absence of human immunodeficiency virus (HIV) infection. Including our newly reported case, 9 of the 208 patients (4.3 %) had Good syndrome. Twenty-one of the 208 patients (10.1 %) had CMVR related to intraocular or periocular corticosteroid administration. The remaining 178 patients (85.6 %) acquired CMVR from other causes. Within the subset of patients who did not have Good syndrome or did not acquire CMVR followed by intraocular or periocular corticosteroid administration, there were many other factors contributing to a decline in immune function. The most common included age over 60 years (33.1 %), an underlying malignancy (28.7 %), a systemic autoimmune disorder requiring systemic immunosuppression (19.1 %), organ (15.2 %) or bone marrow (16.3 %) transplantation requiring systemic immunosuppression, and diabetes mellitus (6.1 %). Only 4.5 % of the patients had no identifiable contributor to a decline in immune function. While the clinical features of CMVR are generally similar in HIV-negative and HIV-positive patients, the rates of moderate to severe intraocular inflammation and of occlusive retinal vasculitis appear to be higher in HIV-negative patients.

Keywords: Herpetic retinitis, Immunosuppression, Thymoma, Uveitis, Good syndrome

Review

Introduction

Thymoma is an uncommon and slow-growing neoplasm that accounts for approximately 20 to 30 % of mediastinal masses in adults and 1 % in children [1]. Thymic tumors not only usually present with respiratory symptoms due to compression of the upper airways and/or superior vena cava syndrome but also can produce paraneoplastic or parathyroid syndromes [1–4], and the most common of which are myasthenia gravis (MG), pure red cell aplasia (PRCA), and acquired partial immune deficiency or Good syndrome [5, 6].

Good syndrome was first described by the American hematologist-oncologist Dr. Robert Good in 1956 [7]. Good noted a direct relationship between the presence of thymoma and hypogammaglobulinemia causing immunosuppression in those patients. Good syndrome typically occurs in middle-aged adults and is associated most commonly with recurrent sinus and pulmonary infections, cytomegalovirus (CMV) disease (most often retinitis), fungal infections, pure red cell aplasia, and myasthenia gravis [8]. While hypogammaglobulinemia in the setting of thymoma defines Good syndrome, other, often partial, immune deficiencies have also been described, including decreased T cell function [9].

We describe a 65-year-old woman who developed CMV retinitis (CMVR) in the setting of Good syndrome. The patient subsequently developed vitritis with cystoid...
macular edema (CME) despite control of the retinitis with antiviral agents. Cases of CMVR in human immunodeficiency virus (HIV)-negative patients, including those with Good syndrome, identified in PubMed through December, 2014, were reviewed and are summarized. Search terms included “Cytomegalovirus AND eye” and “cytomegalovirus retinitis.” Additional publications were identified by reviewing collected references.

Case report

A 65-year-old Thai woman presented for evaluation of suddenly decreased vision with floaters in her right eye. Past ocular history was unremarkable. Past medical history was notable for PRCA diagnosed 2 years prior to presentation and for which she was treated for four months with erythropoietin and systemic corticosteroids. She also had two prior episodes of oropharyngeal candidiasis, which were treated successfully. There was no history of recent or current corticosteroid use.

The best-corrected vision was 20/100 on the right eye and 20/25 on the left eye. Intraocular pressure (IOP) was 15 mmHg bilaterally. No afferent pupillary defect was noted. Anterior segment examination of the right eye showed trace anterior chamber cell but was otherwise normal. Anterior segment examination on the left eye was unremarkable. Posterior segment examination on the right showed moderate vitreous inflammation and an advancing edge of necrotizing retinitis associated with scattered intraretinal hemorrhages and retinal vascular telangiectasis (Fig. 1a). Posterior segment examination of the left eye was unremarkable. The patient was diagnosed clinically with viral retinitis, an anterior chamber paracentesis was performed for viral DNA testing, a laser barrier was applied immediately posterior to the area of active retinitis, and the patient was given an intravitreal injection of 2 mg of ganciclovir followed by treatment with high-dose oral valaciclovir, 2 g three times daily. Analysis of the anterior chamber paracentesis was positive for CMV DNA, and the patient was switched from valaciclovir to valganciclovir, which resulted in resolution of the area of retinitis.

The patient subsequently underwent HIV and syphilis testing, colonoscopy, chest X-ray, bone marrow biopsy, and abdominal CT, all of which were negative. Testing of immune function revealed a markedly decrease total B cell (CD19) cell count and panhypogammaglobulinemia (Table 1).

Within 1 month of the diagnosis of CMVR, the patient was hospitalized for acute pneumonia. During this hospitalization, a mediastinal mass was discovered on chest X-ray and evaluated further by chest CT (Fig. 2). Computer tomography guided thymus biopsy and subsequent thymectomy were performed, revealing histological changes consistent with thymoma that lead to the diagnosis of Good syndrome. Immunoglobulin A, G, and M levels remained low at the last testing 5 months following removal of the thymus. The patient then returned with worsening vision in the eye with CMVR while on maintenance valganciclovir therapy, 450 mg twice daily.

The best-corrected vision was 20/125 on the right eye and 20/25 on the left eye. Intraocular pressure was normal. No afferent pupillary defect was noted. Anterior segment examination on the right showed several areas of retinal edema associated with retinal hemorrhages and retinal vascular telangiectasis (Fig. 1b). Fluorescein angiography (c) and SD-OCT imaging (d) showed the development of cystoid macular edema consistent with the diagnosis of immune recovery uveitis.
stellate keratic precipitates on the corneal endothelium, one cell per high powered field in the anterior chamber, and occasional anterior vitreous cells. Anterior segment examination on the left was unremarkable. Posterior segment examination on the right showed mild to moderate vitreous inflammation, a posterior vitreous detachment, a large area of inactive retinal necrosis (Fig. 1b), continuous laser barrier scars immediately posterior to the area of retinitis, and loss of the foveal light reflex suggestive of CME. Posterior segment examination on the left was unremarkable. Fluorescein angiography confirmed the presence of severe CME on the right (Fig. 1c). Spectral domain optical coherence tomography (SD-OCT) imaging showed marked CME on the right (Fig. 1d) with a central macular thickness of 743 um. SD-OCT imaging of the left fovea revealed a normal contour with no evidence of subretinal or intraretinal fluid. The patient was treated with topical difluprednate four times daily for 1 month. The CME persisted, the difluprednate was stopped, and the patient was given two injections of 1.25 mg of intravitreal bevacizumab, 1 month apart. The CME failed to respond, and so the patient was given an intravitreal injection of triamcinolone acetonide, 2.0 mg, following which the CME resolved and vision improved to 20/80 in the affected eye. The CME subsequently recurred and the vision decreased to 20/100, but the patient refused further treatment. The retinitis remained inactive.

Comprehensive literature review

We describe a patient who developed CMVR in the setting of Good syndrome, a rare occurrence reported in eight previous patients to date (Tables 2 and 3) [10–16]. Including our patient, reported ages of the nine patients ranged from 48 to 68 years, with both a mean and median of 56 years. Women constituted just over half of the reported patients (55.5 %), with retinitis occurring unilaterally in all but one patient (88.9 %) and involving zone 1 in nearly two thirds of the affected eyes (62.5 %). When reported, anterior chamber inflammation was present in 62.5 % of cases; vitritis was present in 88.8 % of cases and was reported to be moderate to severe in five cases (55.5 %). The diagnosis was confirmed in all but one patient (89.9 %) by polymerase chain reaction (PCR)-based testing of intraocular fluids, and all cases responded to antiviral therapy, which was administered both intravitreally and systemically in six of nine (66.6 %) patients. While the CMVR in our patient occurred 1 month prior to the identification of thymoma, a thymic tumor was identified prior to the development of CMVR in the other eight patients, with a time ranging from 1 month to just over 6 years prior to the occurrence of retinitis. Visual acuity at the initial CMVR diagnosis was between 20/40 and 20/200 in 77.8 and worse than 20/200 in 22.2 % of eyes, whereas visual acuity at last follow-up (median 6 months; range 1.5–7 months)

Table 1 Immunologic profile over time of currently reported case of cytomegalovirus retinitis in the setting of thymoma (Good’s syndrome)

| Immunologic profile | At time of retinitis | At time of CME diagnosis and 5 months after thymoma resection | 6 months after CME and 11 months after thymoma resection | Reference range |
|---------------------|---------------------|---------------------------------------------------------------|----------------------------------------------------------|-----------------|
| T cells CD3         | 1079 (70 %)         | N/A                                                           | 1284 (81 %)                                              | 672–2638 cells/mL (54–83 %) |
| T helper cells CD4  | 480 (31 %)          | N/A                                                           | 437 (28 %)                                               | 292–1366 cells/mL (23.1–51.0 %) |
| Cytotoxic T cells CD 8 | 540 (35 %)     | N/A                                                           | 817 (51 %)                                               | 240–1028 cells/mL (17.9–47.5 %) |
| CD4 to CD8 ratio    | 0.88                | N/A                                                           | 0.53                                                     | 0.6–2.5 |
| B cells CD19        | 40 (3 %)            | N/A                                                           | 26 (2 %)                                                 | 82–560 cells/mL (5.1–20.8 %) |
| Natural killer cells CD16/56 | 413 (27 %) | N/A                                                           | 277 (17 %)                                               | 130–938 cells/mL (7.1–38.0 %) |
| Immunoglobulin G    | 2.24                | 1.91                                                          | N/A                                                      | 8–18 (g/L) |
| Immunoglobulin M    | <0.06               | <0.06                                                         | N/A                                                      | 0.5–2.2 (g/L) |
| Immunoglobulin A    | <0.04               | 0.6                                                           | N/A                                                      | 1.1–5.6 (g/L) |

Abbreviations: CME cystoid macular edema, CMV cytomegalovirus, NR not reported, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, CD cluster designation, NK natural killer, N/A not available

Fig. 2 Chest CT showing a large mediastinal mass outlined in red and found subsequently to be a thymoma
| Author (year) | Age (years) | Gender | Unilateral (U) or bilateral (BL) | Timing of CMV retinitis relative to thymoma diagnosis (months) | Associated opportunistic infections | Zone (involved) | Retinitis treatment | CMV testing | Vision when retinitis was first diagnosed | Follow-up (months) | Vision at the last visit |
|---------------|-------------|--------|----------------|-------------------------------------------------|-----------------------------------|-----------------|----------------|------------------|------------------------|-------------------|-----------------------|
| Ho et al. (2010) | 68 | M | U | 75 | Recurrent pneumonia; disseminated CMV; CMV colitis | Zone I | IV ganciclovir and then PO valganciclovir | Lung biopsy | 20/200 | 1 | 20/100 |
| Mateo-Montoya et al. (2010) | 57 | M | U | NR. "Long time after thymoma" | Recurrent pneumonia; Campylobacter sepsis | Zone I | IVT ganciclovir, IVT foscarnet, and IV ganciclovir then PO valganciclovir | Aqueous PCR, vitreous PCR | 20/100 | 6 | 20/40 |
| Park et al. (2009) | 56 | M | BL | 3 months after thymoma | NR | Zone I and zone II | IVT ganciclovir and IV ganciclovir, then PO valganciclovir | Aqueous PCR; serum IgG | 20/800 OD, 20/125 OS | 6 | CF at 30 cm OD, NLP OS |
| Sen et al. (2005) | 48 | M | U | 60 months after thymoma | Pneumocystis jiroveci pneumonia; history of retinitis and optic neuropathy | Zone I | IVT ganciclovir and IVT ganciclovir implant (Vitrasert) | Aqueous PCR | 20/200 | 7 | 20/200 |
| Wan et al. (2012) | 51 | F | U | 60 months after thymoma | Recurrent sinopulmonary infections; CMV enterocolitis | Zone II | PO valganciclovir then IVT ganciclovir weekly | Vitreous PCR | 20/40 | 6 | 20/50 then subsequently to CF due to the development of autoimmune retinopathy |
| Yong et al. (2008) | 50 | F | U | 6 months after thymoma | Herpes zoster (T10 dermatome) | NR | IV ganciclovir, then PO valganciclovir | Vitreous PCR | NR | 2 | NLP |
| Assi et al. (2002) case 1 | 45 | F | U | 24 months after thymoma | Recurrent pneumonia; zoster dermatitis | Zone II and zone III | IV valaciclovir, then IVT ganciclovir implant | Vitreous PCR | 20/40 | 6 weeks | NR |
| Assi et al. (2002) case 2 | 65 | F | U | 24 months after thymoma | Recurrent pneumonia | Zone I | IVT foscarnet then PO ganciclovir | Vitreous PCR | HM | NR | HM |
| Current case Downes, et al. (2016) | 65 | F | U | 1 month before thymoma | Oropharyngeal candidiasis; Candida | Zone II and zone III | IVT ganciclovir, then PO valganciclovir | Aqueous PCR | 20/100 | 7 | 20/80 |
### Table 2 Summary of the current and previously reported cases of cytomegalovirus (CMV) retinitis in the setting of immunodeficiency associated with thymoma (Good syndrome) (Continued)

| Summary | Total n = 9 | Mean: 56 years | Male: 4/9 (44.4 %) | Retinitis diagnosed after thymoma: 8/9 (88.9 %) | Respiratory infections: 7/9 (77.8 %) | Zone I: 5/8 reported (62.5 %) | Intravitreal therapy alone: 1/9 (11.1 %) | Positive aqueous PCR: 4/9 (44.4 %) | Acuity better than 20/40: 0/9 eyes (0.0 %) | Mean = 4.56 months | Acuity better than 20/40: 0/9 eyes (0.0 %) |
|---------|-------------|----------------|-------------------|-----------------------------------------------|-------------------------------------|-------------------------------|-----------------------------------|-----------------------------------|----------------------------------------|----------------|----------------------------------------|
| Median: | Female: 56 years (55.5 %) | Mean = 3.14 months after thymoma | Non-ocular CMV: 2/9 (22.2 %) | Zone II: 4/8 reported (50 %) | Systemic therapy alone: 2/9 (22.2 %) | Positive vitreous PCR: 5/9 (55.5 %) | Acuity between 20/40 and 20/200: 7/9 eyes (77.8 %) | Median = 6 months | Acuity between 20/40 and 20/200: 5/9 eyes (55.5 %) |
| Range: 48–68 years | Male to female ratio 0:8:1 | Median = 24 months after thymoma | Other opportunistic infections: 3/9 (33.3 %) | Zone III: 2/8 reported (25 %) | Combo intravitreal and systemic therapy: 6/9 (66.6 %) | Confirmed by other means: 1/9 (11.1 %) | Acuity worse than 20/200: 2/9 eyes (22.2 %) | Range = 1.5–7 months | Acuity worse than 20/200: 4/9 eyes (44.4 %) |

Abbreviations: IgG immunoglobulin G, M male, F female, U unilateral, BL bilateral, CMV cytomegalovirus, NR not reported, CF count fingers, NLP no light perception, LP light perception, HM hand motion, IV intravenous, PO per oral, IVT intravitreal, PCR polymerase chain reaction

*All patients were tested for HIV and found to be negative*

*Zone definitions are as follows: zone I defined as macula or optic nerve involvement; zone II defined as mid-periphery; and zone 3 defined as outer periphery. Zone definitions referenced in this paper: Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507–8 [115]*

*Dosing with each modality varied widely across studies*
| Author (year)        | Myasthenia gravis | Pure red cell aplasia | Other conditions encountered | Lymphopeniaa | Low CD3+ T cells (<672 cells/mL or <54 %) | Low CD4+ count (<360/μL or <36 %) |
|----------------------|-------------------|-----------------------|-----------------------------|--------------|----------------------------------------|---------------------------------|
| Ho et al. (2010) [10]| –                 | –                     | None                        | +            | +                                      | +                               |
| Mateo-Montoya et al. (2010) [11]| +                     | –                     | None                        | NR           | NR                                     | NR                              |
| Park et al. (2009)[12]| –                 | –                     | None                        | +            | NR                                     | NR                              |
| Sen et al. (2005) [13]| –                 | –                     | Neurosensory hearing loss and optic neuropathy | NR           | NR                                     | +                               |
| Won et al. (2012) [14]| NR                | +                     | Autoimmune retinopathy (many years after diagnosis of retinitis) | NR           | NR                                     | NR                              |
| Yong et al. (2008) [15]| –                 | –                     | None                        | +            | –                                      | +                               |
| Assi et al. (2002) [16] case 1 | +                     | –                     | None                        | –            | NR                                     | +                               |
| Assi et al. (2002) [16] case 2 | –                 | –                     | None                        | NR           | NR                                     | NR                              |
| Current case         | Downes, et al. (2013) | –             | None                        | –            | –                                      | –                               |
| Summary              | Total n = 9        | +2/8 reported (25.0 %) | +2/9 cases (22.2 %)         | +3/5 reported (60.0 %) | +1/3 reported (33.3 %) | +5/6 reported (83.3 %) |
| A low CD8+ count (<240 cells/μL) | Low CD4+/CD8+ ratio (<0.6) | Low NK cells (<130 cells/mL or <7.1 %) | Hypogammaglobulinemia IgG (IgG < 8 g/L) | Hypogammaglobulinemia IgM (IgM < 0.5 g/L) | Hypogammaglobulinemia IgA (IgA < 1.1 g/L) | Panhypogammaglobulinemia (IgG < 8 g/L, IgM <0.5 g/L, IgA < 1.1 g/L, or total Ig < 9.6 g/L) |
|---------------------------------|----------------------------|----------------------------------|---------------------------------------|----------------------------------------|----------------------------------------|------------------------------------------|
| NR                              | NR                        | NR                               | +                                    | +                                     | +                                     | +                                       |
| NR                              | NR                        | NR                               | +                                    | +                                     | +                                     | +                                       |
| NR                              | +                         | NR                               | +                                    | +                                     | +                                     | +                                       |
| NR                              | +                         | NR                               | –                                    | +                                     | +                                     | +                                       |
| –                               | +                         | NR                               | –                                    | +                                     | +                                     | +                                       |
| –                               | –                         | –                                | –                                    | +                                     | +                                     | +                                       |
| +0/4 reported (0.0 %)           | +5/6 reported (83.3 %)     | +1/2 reported (50.0 %)           | +7/8 reported hypo IgG (87.5 %)       | +7/8 reported hypo IgM (87.5 %)       | +8/8 reported hypo IgA (87.5 %)        | +7/8 reported panhypogammaglobulins (87.5 %) |

**Abbreviations:** CMV cytomegalovirus, NR not reported, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, CD cluster designation, NK natural killer

*Based on each individual lab standards and if reported by authors*
was between 20/40 and 20/200 in 55.5 and worse than 20/200 in 44.4 % of eyes. Other common opportunistic infections reported in these nine patients with Good syndrome and CMVR included respiratory infections (77.8 %), non-ocular CMV (22.2 %), and herpes zoster dermatitis (33.3 %), whereas other autoimmune diseases (Table 3) included MG (25.0 %) and PRCA (22.2 %).

Although the retinitis in our patient responded promptly to intravitreal and systemic antiviral agents, the patient subsequently developed vitritis and CME of the type seen in patients with immune recovery uveitis (IRU) despite the fact that her total CD4+ T cell count was normal both before and after the occurrence of retinitis. In contrast, the total B cell count and immunoglobulin levels where low both before and after thymectomy. While hypogammaglobulinemia is required to diagnose Good syndrome and has been observed in all reported cases to date, including our patient, it is noteworthy that the total CD4+ T cell count was somewhat decreased in five of the eight previously reported cases with Good syndrome and CMVR (Table 3), indicating that partial CD4+ T cell depletion does occur in patients with Good syndrome and suggesting the possibility that selective loss of CMV-targeting CD4+ T cells may have occurred in our patient, facilitating the development of retinitis. To our knowledge, an IRU-like syndrome has not been reported previously following treatment of CMVR in a patient with Good syndrome.

Our review identified a total of 248 eyes of 178 patients previously reported with CMVR in the absence of either HIV infection, Good syndrome, or prior periocular or intraocular corticosteroid injection (Additional file 1: Table S1) [17–86]. Reported ages ranged from 1 week to 84 years, with a mean and median of 45.7 and 48.0 years, respectively. Men outnumbered women approximately two to one (M to F ratio = 1.88:1), and the vast majority (95.5 %) had an identifiable cause of systemic immunosuppression. The most common factors contributing to a decline in immune function included age over 60 years (33.1 %), an underlying malignancy (28.7 %), a systemic autoimmune disorder requiring treatment (19.1 %), organ (15.2 %) or bone marrow (16.3 %) transplantation requiring systemic immunosuppression, and diabetes mellitus (6.1 %). The most commonly reported cancers included leukemia (35 patients; 19.7 %) and lymphoma (14 patients; 7.9 %). Three patients had multiple myeloma (1.7 %). One patient each (0.6 %) had breast cancer and angiogenic immunoblastic lymphadenopathy with dysproteinemia. Several patients had a primary immune deficiency other than Good syndrome, including three patients (1.7 %) with severe combined immunodeficiency, two patients each (1.1 %) with unspecified primary immune deficiency and common variable immune deficiency, and one patient (0.6 %) with idiopathic CD4+ T cell lymphopenia. Among the 26 reported patients less 18 years of age, 9 (34.6 %) had acute lymphoblastic leukemia, 8 (30.8 %) had undergone bone marrow transplantation, 5 (19.2 %) had congenital CMV infection, 3 (11.5 %) had severe combined immunodeficiency and 1 each (3.8 %) had common variable immune deficiency and immunoglobulin 2 (Ig2) deficiency.

The use of systemic immunosuppressive medication was reported in 105 of 160 cases (65.6 %). Seventy-eight of these 105 patients (74.3 %) were on two or more immunosuppressive agents. Corticosteroids were the most common immunosuppressive agent used in 69 patients (65.7 %), followed by cyclophosphamide in 33 patients (31.4 %), azathioprine in 17 patients (16.2 %), vincristine in 16 patients (15.2 %), methotrexate in 15 patients (14.3 %), cyclosporine in 13 patients (12.4 %), tacrolimus in 11 patients (10.5 %), 6-mercaptopurine in 9 patients (8.6 %), mycophenolate mofetil in 8 patients (7.6 %), fluorarabine in 7 patients (6.7 %), and adriamycin in 6 patients (5.7 %). Five patients each (4.8 %) used intravenous immunoglobulin G and rituximab. One patient each (1.0 %) was on mitoxantrone, ibritumomab tiuxetan, and hydroxychloroquine. Within the 105 cases reporting medication use, the use of either an antimetabolite or a leukocyte signaling inhibitor as a group (methotrexate, azathiprine, mycophenolate mofetil, tacrolimus, or cyclosporine) was reported in 46.7 % of cases, whereas chemotherapeutic agents as a whole (cyclophosphamide, vincristine, high-dose methotrexate, 6-mercaptopurine, adriamycin, rituximab, fluorarabine, mitoxantrone, and ibritumomab tiuxetan) were reported in 48.6 % of cases. Clinically, the retinitis was unilateral in 108 out of 178 cases (60.7 %). Many case reports provided limited clinical information, but the location was either reported or illustrated in 97 out of the 248 eyes (39.1 %) and was found to involve zone 1 in 72 eyes (74.2 %). Additional clinical features were noted in 200 out of 248 eyes (80.6 %). Among these, 200 eyes, or just under one third (29.0 %), were noted to have anterior chamber inflammation, which was described as mild in 18 (9.0 %) and moderate in 13 (6.5 %), and severe in the remaining 27 (13.5 %). Just over one third of the reported eyes (37.5 %) were noted to have vitreous inflammation, among which inflammation was described as mild in 23 (11.5 %), moderate in 18 (9.0 %), and severe in 6 (3.0 %), with the remaining 28 (14.0 %) not quantifying severity. An occlusive vasculitis was noted in 47 eyes (23.5 %). Visual acuity at initial CMVR diagnosis was reported in 179 of 248 eyes (72.2 %). Among these 179 eyes, visual acuity at initial diagnosis was better than 20/40 in 34.1 %, between 20/40 and 20/200 in 39.1 %, and worse than 20/200 in 26.8 % of eyes. The method of diagnostic confirmation of CMVR was reported in 131 of the 178 cases (73.6 %), among which the diagnosis of CMVR was
confirmed by PCR-based testing of intraocular fluids in 71.8 %. The retinitis responded to antiviral therapy in all cases. The treatment administered was reported in 126 of the 178 cases (70.8 %). Of these 126 cases, systemic treatment was administered in 45.2 % of patients, whereas both intravitreal and systemic therapy was given in 31.0 % of patients, and intravitreal treatment alone was employed in 23.8 % patients. Visual acuity at the last follow-up visit was reported in 171 eyes (mean 14.2 months; median 6.0 months; range 0 to 216 months) and was better than 20/40 in 30.4 %, between 20/40 and 20/200 in 37.4 %, and worse than 20/200 in 32.2 % of eyes.

Recently, Takakura and colleagues reviewed the literature on patients who developed viral retinitis following intraocular or periocular administration of corticosteroids [87]. Out of a total of 30 reported cases, 21 (70.0 %) developed CMVR (Table 4) [33, 87–100]. These 21 patients constituted 10.1 % of the total of 208 non-HIV-positive patients with CMVR identified in our review. Among the 21 patients with CMVR, reported ages ranged from 30 to 84 years, with a mean and median of 66 and 69 years, respectively, and men outnumbered women two to one (M to F ratio = 2:1). The most common underlying ocular diseases for which corticosteroids were injected included diabetes mellitus (38.0 %), retinal vein occlusion (33.3 %), and uveitic CME (33.3 %), followed by choroidal neovascularization secondary to age-related macular degeneration (9.5 %). In patients with uveitis and CMVR, Behcet’s disease and anterior uveitis comprised two cases each (28.5 %), followed by each case one (14.3 %) of anterior uveitis, Vogt-Koyangi-Harada disease, idiopathic posterior uveitis, and idiopathic panuveitis. The corticosteroid was administered intravitreally in 19 of the 21 eyes (90.5 %). Among these 19 patients who received intravitreal corticosteroids, 8 (38.0 %) were administered between 1.5 and 4 mg, 4 (19.0 %) were administered between 8 and 20 mg, and 1 (4.8 %) was administered 40 mg of triamcinolone acetonide. Two (9.0 %) were implanted with the fluocinolone acetonide intravitreal implant (Retisert®). Among the two patients who received periocular corticosteroids, one (4.8 %) was administered 20 mg triamcinolone acetonide while the other patient (4.8 %) was administered 40 mg. The median time to developing retinitis after corticosteroid administration was 4.3 months with a mean of 4.0 months and a range 7 days to 13 months. Clinically, the retinitis involved zone 1 in 20.0 % of the eyes and was both unilateral and ipsilateral to the injection in all cases. Twelve out of 21 cases (57.1 %) described some clinical features of the retinitis. Within these 12 eyes, 10 (83.3 %) were noted to have anterior chamber inflammation, among which the inflammation was described as mild in one case (8.3 %) and moderate in four cases (33.3 %)—with the remaining seven (58.3 %) not quantifying severity. Over ninety percent of the eyes (91.6 %) were noted to have vitreous inflammation, among which inflammation was described as moderate in four eyes (33.3 %) with the remaining seven (63.6 %) not quantifying the severity of the inflammation. An occlusive vasculitis was noted in seven eyes (58.3 %). Visual acuity at initial CMVR diagnosis was reported in all 21 eyes and was better than 20/40 in 2 eyes (9.5 %), between 20/40 and 20/200 in 11 eyes (52.3 %), and worse than 20/200 in 8 eyes (38.0 %). The diagnosis was confirmed by PCR-based testing of intraocular fluids in 95.2 % of cases, and all cases responded to antiviral therapy, which was administered both intravitreally and systemically in 11 patients (52.3 %). Visual acuity at the last follow-up visit (mean 11.8 months; median 5.5 months; range 1–84 months) was better than 20/40 in 2 eyes (9.5 %), between 20/40 and 20/200 in 8 eyes (38.0 %), and worse than 20/200 in 11 eyes (52.3 %).

The most complete and standardized description of CMVR in HIV-positive patients comes from the studies performed by the Studies of the Ocular Complications of AIDS (SOCA) research group [101–103]. Cytomegalovirus retinitis was the most frequently encountered complication of HIV infection in this cohort, occurring in 34.6 % of patients with CD4+ T cell counts <50 cells/µL and in 63.4 % of patients with CD4+ T cell counts <200 cells/µL [104]. Clinically, HIV-associated CMVR includes classic features of necrotizing retinitis with irregular sheathing of adjacent vessels and variable degrees of hemorrhage (sometimes referred to as “pizza pie retinopathy” or “cottage cheese with ketchup”), and which is sometimes coupled with a frost branch angiitis appearance without vascular occlusion and often associated with mild vitreous or anterior chamber inflammation [12, 20, 104]. In addition to these core clinical findings previously listed, the SOCA studies quantified the prevalence of a number of hallmark features of CMVR at presentation. Specifically, keratic precipitates were present in 36.8 % of the eyes with CMVR, anterior chamber inflammation in 46.2 %, and vitreous inflammation in 61.9 %. The prevalence of anterior chamber cells greater than 2+ was 1.9 % and vitreous haze greater than 2+ was 11.4 %. Macular edema, epiretinal membrane formation, and rhegmatogenous retinal detachment were each uncommon at presentation in the SOCA cohort, occurring in less than 10 % of the eyes, and posterior synechia formation was not observed [104].

A number of studies have suggested that the clinical presentation of CMVR in HIV-negative patients can differ from that in HIV-positive patients [20–23, 27, 36, 94]. In a small series of eyes with CMVR in HIV-negative patients compiled by Maguire and associates in 1995, three eyes were found to have spontaneously
## Table 4 Summary of previously reported HIV-negative cases of cytomegalovirus retinitis following intraocular and periocular corticosteroid injection

| Previously published cases | Author (year) | Age (years) | Gender | Unilateral (U) or bilateral (BL) | Indication for corticosteroid | Corticosteroid dose/route | Time from corticosteroid dosing to retinitis (months) | CMV testing | Zone involved<sup>a</sup> | Vision when retinitis was first diagnosed | Retinitis treatment<sup>b</sup> | Follow-up (months) | Vision at the last Visit |
|----------------------------|---------------|-------------|--------|----------------------------------|-------------------------------|-----------------------------|---------------------------|-------------|----------------|---------------------------------|--------------------------|--------------------------|-------------------------------|
| Saidel et al. (2005) [88]  | 75            | M           | U      | DME                              | 4 mg IVTA                     | 4.0                         | CMV retinitis (PCR)       | Zone I      | 20/400 | IV ganciclovir, then IV valganciclovir, repeated IVT ganciclovir | 6                        | 20/400                   |
| Delyfer et al. (2007) [89] Case 1 | 77            | M           | U      | CNVM/AMD                         | 20 mg IVTA                    | 4.0                         | CMV retinitis (serology + PCR) | Zone II     | CF at 1.8 m | IVT, IV valganciclovir         | 6                        | 20/200                   |
| Delyfer et al. (2007) [89] Case 2 | 69            | M           | U      | CRVO/DME                         | 8 mg IVTA three times over a 3-month interval | 3 (after the 3rd IVTA) | CMV retinitis (PCR)       | Zone I      | 20/200 | IV ganciclovir and IV valganciclovir | 3                        | 20/400                   |
| Furukawa et al. (2007) [90] | 54            | F           | U      | DME                              | 10 mg IVTA                    | 4.0                         | CMV retinitis (serology + PCR) | Zone II     | 1     | IV ganciclovir; IVT foscarnet; vitrectomy and silicone oil tamponade | 14                       | 0.5                      |
| Hsu et al. (2007) [91]     | 77            | M           | U      | DME                              | 4 mg IVTA                     | 1.5                         | CMV retinitis (PCR)       | Zone II     | 3/200 | Valganciclovir                | 1                        | 20/400                   |
| Ufret-Vincenty et al. (2007) [92] | 65            | M           | U      | Uveitic CME/Behcet's disease     | FA implant                    | 53 (after the 1st implant), 5 (after the 2nd implant) | CMV retinitis ("clinical diagnosis") | Zone II     | 20/50 | IVT foscarnet; ganciclovir implant | 5                        | 20/40                    |
| Park et al. (2008) [93]    | 77            | F           | U      | CRVO/CME due to HTN              | 4 mg IVTA                     | 4.0                         | CMV retinitis (PCR)       | Zone II     | LP    | IVT ganciclovir               | 4                        | HM                      |
| Sekiryu et al. (2008) [94] | 63            | M           | U      | BRVO/DME                         | 4 mg IVTA                     | 7.0                         | CMV retinitis (PCR)       | Zone II     | 0.1   | IV ganciclovir, IV valganciclovir | 1                        | 0.6                      |
| Babiuch et al. (2010) [95] | 77            | M           | U      | Idiopathic iritis                | 40 mg PST TA                  | 0.25                        | CMV retinitis (serology + PCR) | Zone II     | 20/40 | Vitrectomy, endolaser; IVT ganciclovir; ganciclovir implant | NR                       | NR                      |
| Shah et al. (2010) [96]    | 62            | M           | U      | BRVO/DME                         | 20 mg IVTA x 2                | 6.5                         | CMV retinitis (PCR)       | Zone II     | 20/400 | IV valaciclovir; vitrectomy, endolaser and silicone oil; then IV valganciclovir | NR                       | NR                      |
| Toyokawa et al. (2010) [97] | 83            | M           | U      | CNVM/AMD                         | 20 mg PST TA                  | 3.0                         | CMV retinitis (PCR)       | Zone II     | 0.3   | PO valaciclovir, vitrectomy | 5                        | 0.1                      |
| Study (Year) | Case | Gender | Diagnosis | IVTA dose | CMV Retinitis | Zone | Acuity | Therapy Details |
|-------------|------|--------|-----------|-----------|---------------|------|--------|----------------|
| Tugal-Tutkun et al. (2010) [98] | 30 | M | Behcet's panuveitis | IVTA dose NR | CMV retinitis (serology + PCR) | Zone I, zone II, zone III | 20/200 | IVT ganciclovir × 2; IV ganciclovir x 5 weeks; azathioprine changed to interferon alpha 2a |
| Vertes et al. (2010) [99] | 78 | F | BRVO/CME | 4 mg IVTA | CMV retinitis (serology + PCR) | Zone II | 20/40 | IV ganciclovir; PO ganciclovir; IVT ganciclovir; then vitrectomy, endolaser |
| Zaborowski et al. (2013) [100] | 56 | F | Idiopathic panuveitis/Uveitic CME | 4 mg IVTA | CMV retinitis (PCR) | Zone II | CF | Azathioprine discontinued; intravitreal ganciclovir twice weekly for 3 weeks (2 mg) |
| Gupta et al. (2013) [32] | 70 | F | DME | IVTA dose NR | CMV retinitis (PCR) | Zone II | CF | IVT foscarnet; IV valganciclovir; intravitreal ganciclovir; ganciclovir implant |
| Gupta et al. (2013) [32] | 60 | M | DME | IVTA NR | CMV retinitis (PCR) | NR | 20/400 | intravitreal foscarnet; IV valganciclovir; ganciclovir implant |
| Gupta et al. (2013) [32] | 84 | F | BRVO | IVTA NR | CMV retinitis (PCR) | Zone II | 20/150 | IVT foscarnet; IV valganciclovir |
| Takakura et al. (2013) [87] | 66 | M | VKH with steroid-induced cataracts and ocular hypertension, IVTA given during cataract surgery | 4 mg IVTA and ASCTA | CMV retinitis (PCR) | Zone II | 20/200 | IVT ganciclovir, PO valganciclovir; methotrexate and low-dose oral prednisone |
| Takakura et al. (2013) [87] | 37 | F | Bilateral idiopathic posterior uveitis complicated by CME/retinal vasculitis | FA implant | CMV retinitis (PCR) | Zone I | 20/80 | IVT foscarnet; PO valganciclovir |
| Takakura et al. (2013) [87] | 63 | M | Granulomatous uveitis with CME | 40 mg IVTA × 2 | CMV retinitis (PCR) | Zone II | 20/60 | IV ganciclovir; PO prednisone; PPV |
| Takakura et al. (2013) [87] | 72 | M | BRVO | 4 mg IVTA | CMV retinitis (PCR) | Zone II | 20/60 | IVT ganciclovir |

**Summary**

- **N** = 21
- **Mean, 66.4 years**
- **Male, 14/21 (66.6%)**
- **Female, 7/21 (33.3%)**
- **1.5–4 mg IVT, 8/21 (38.0%)**
- **40 mg IVTA × 2, 2 (100%)**
- **Positive aqueous or vitreous PCR, 20/21 (95.2%)**
- **Zone I, 4/20 reported (20.0%)**
- **Zone II, 17/20 reported (85.0%)**
- **Acuity better than 20/40, 5/21 (23.8%)**
- **Acuity between 20/40 and 20/400, 8/21 (38.0%)**
- **Acuity between 20/400 and 20/2000, 6/21 (28.6%)**
- **Mean, 4.3 months**
- **Mean, 4.0 months**
- **Mean = 11.8 months**
- **Mean = 5.5 months**
- **Acuity better than 20/40: 5/21 eyes (9.5%)**
- **Acuity between 20/40 and 20/200: 8/21 eyes (38.0%)**

**Table 4 Summary of previously reported HIV-negative cases of cytomegalovirus retinitis following intraocular and periocular corticosteroid injection (Continued)**
Table 4 Summary of previously reported HIV-negative cases of cytomegalovirus retinitis following intraocular and periocular corticosteroid injection (Continued)

| Range, 30.0–84.0 year | Male to female ratio, 2:1 | Uveitic CME, 7/21 (33.3 %) | 40 mg, 2/21 (9.0 %) | Range, 0.25–13.0 months | Zone III, 1/20 reported (5.0 %) | Acuity worse than 20/200, 8/21 eyes (38.0 %) | Intravitreal and systemic therapy, 11/21 (52.3 %) | Range = 1–84 months | Acuity worse than 20/200: 11/21 eyes (52.3 %) |
|------------------------|--------------------------|-----------------------------|-------------------|--------------------------|---------------------------------|-----------------------------------|-----------------------------------------------|--------------------------|-----------------------------------------------|
| CNVM due to AMD, 2/21 (9.5 %) | FA implant, 2/21 (9.0 %) | Range, 1.5–40 mg |
| IRU, 0/21 (0.0 %) |

Data used from paper done by Takakura et al (2013) currently in peer review: Ocular Immunology and Inflammation

Abbreviations: AMD age-related macular degeneration, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, CNVM choroidal neovascular membrane, DME diabetic macular edema, ERM epi-retinal membrane, FA fluocinolone acetonide, IRU immune recovery uveitis, IgG immunoglobulin G, CMV cytomegalovirus, NR not reported, PCR polymerase chain reaction, CD cluster designation, NK natural killer, N/A not applicable

*Zone definitions are as follows: zone I defined as macula or optic nerve involvement; zone II defined as mid-periphery; and zone 3 defined as outer periphery. Zone definitions referenced in this paper: Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507-8 [115]

*Dosing with each modality varied widely across studies
regressed or indolent appearing CMVR associated with vitritis and CME. The authors suggested that HIV-negative CMVR was more often associated with moderate to severe vitreous inflammation and CME [21]. The tendency for HIV-negative CMVR to have more severe intraocular inflammation as compared to CMVR in HIV-positive patients has since been noted by a number of authors, including Silverstein and colleagues [23], Voros and associates [27], Tajunisah and colleagues [25], Panthanapitoon and associates [22], and Schneider and colleagues [36] with specific mention of a similarity to acute retinal necrosis (ARN) in some eyes, including both the severity of the inflammation and the presence of occlusive vasculitis. In most instances, the more severe inflammation and vascular occlusion was ascribed to relative retention of anti-CMV immunoreactivity. However, other studies have failed to identify consistent difference in clinical presentation based on HIV status [18–20, 24, 26, 30–33, 37–40, 44, 94, 95]. In our review, of all the reported cases to date of HIV-negative CMVR not associated with Good syndrome or following intraocular or periocular administration of corticosteroids, clinical features of the inflammation were reported in 199 of the 248 eyes (80.2 %). Within these 199 eyes, 13 (6.5 %) were specifically described as having moderate to severe anterior chamber inflammation, 24 (12.1 %) as having moderate to severe vitreous inflammation, and 47 (23.6 %) were noted to have occlusive vasculitis. In HIV-negative CMVR associated with Good syndrome, clinical features of the inflammation were reported in all eyes. Within these 10 eyes, only 1 (10.0 %) was specifically described as having moderate to severe anterior chamber inflammation, whereas 5 out of 10 eyes (50.0 %) were described as having moderate to severe vitreous inflammation. None were noted to have occlusive vasculitis. In HIV-negative CMVR following intraocular or periocular administration of corticosteroids, clinical features of the inflammation were reported in 12 of the 21 eyes (57.1 %). Among these 12 eyes, 4 (33.3 %) each were described as moderate to severe anterior chamber inflammation or vitreous inflammation, and 6 (50.0 %) were noted to have occlusive retinal vasculitis. Hence, while an ARN-like picture including moderate to severe intraocular inflammation and the presence of occlusive vasculitis may be somewhat more common in HIV-negative as compared to HIV-positive CMVR, particularly in the setting of Good syndrome or following periocular or intraocular corticosteroids, the clinical presentation in these various cohorts appears, more often than not, to be fairly similar, with an overlapping clinical presentation (Table 5).

Immune recovery uveitis has been well characterized in HIV-positive patients and is currently one of the most common causes of vision loss in patients with CMVR receiving highly active antiretroviral therapy (HAART) [104, 105]. While the occurrence of IRU has varied widely in HIV-positive cohorts receiving HAART, with reported rates ranging from 3.0 to 63.3 % [106], the inflammation generally occurs several weeks to months after initiating HAART, as the number of circulating CD4+ T cells increases. The clinical spectrum of IRU includes vitritis, papillitis, CME, epiretinal membrane formation, vitreous hemorrhage, retinal neovascularization, vitreomacular traction syndrome, and proliferative vitreoretinopathy [104–107].

Of the 248 eyes of 178 patients with CMVR in the absence of either HIV infection or Good syndrome that have been described in the literature (Additional file 1: Table S1), 16 eyes (6.5 %) of 10 patients had one or more features consistent with IRU [17, 20, 45, 50, 70]. Reported ages of these 10 patients ranged from 15 to 68 years, with a mean and median of 47.8 and 54 years, respectively. Men outnumbered women approximately two to one (M to F ratio = 2.3:1), and the 100 % of the cases had an identifiable cause of systemic immunosuppression. The most common factors contributing to a relative decline in immune function included an underlying malignancy (n = 3; 30.0 %), age over 60 years (n = 2; 20.0 %), an autoimmune disorder (n = 2; 20.0 %), organ (n = 3; 30.0 %) or bone marrow (n = 1; 10.0 %) transplantation requiring systemic immunosuppression, and diabetes mellitus (n = 1; 10.0 %). The three reported cancers included two patients with acute lymphoblastic leukemia and one patient with chronic lymphocytic leukemia. The use of systemic immunosuppressive medication was reported in 8 out of the 10 cases (80.0 %). All of these patients were on two or more immunosuppressive agents. Corticosteroids were the most common immunosuppressive agent used in four patients (50.0 %), followed by cyclophosphamide in three patients (37.5 %), and two patients each (25.0 %) treated with vincristine and mycophenolate mofetil. One patient each (12.5 %) was treated with rituximab, fludarabine, methotrexate, and tacrolimus. Clinically, the retinitis was bilateral in 6 (60.0 %) out of 10 cases. Most case reports provided limited clinical information, and the location was either reported or illustrated in only 1 out of the 10 patients (10.0 %). In this patient, the retinitis was found to involve zone II. Additional clinical features were noted in 5 out of 16 eyes (31.3 %). Among these five eyes, just two eyes (40.0 %) were noted to have moderate anterior chamber inflammation. All five eyes (100.0 %) were noted to have vitreous inflammation, among which inflammation was described moderate to severe in all cases. An occlusive vasculitis was not present in any reported case of CMVR associated with IRU. Visual acuity at initial CMVR diagnosis was reported in 15 out of 16 eyes (93.8 %). Among these 15 eyes, visual acuity at initial diagnosis was better than 20/40 in 40.0 %, between 20/40 and 20/200 in 53.3 %, and worse than 20/200 in 6.7 % of eyes. The
Table 5 Summary of cases of CMV retinitis in the literature without human immunodeficiency virus infection

|                                | CMV retinitis following intraocular and periocular corticosteroid injection<sup>a</sup> | CMV retinitis in the setting of immunodeficiency associated with thymoma (Good syndrome) | CMV retinitis in immunocompetent adults (non-Good syndrome) |
|--------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------|
| **Number of cases**            | n = 21, n = 21 eyes                                                                 | n = 9, n = 10 eyes                                                                  | n = 178, n = 248 eyes                                      |
| **Age (years)**                | Mean, 66.4 years                                                                   | Mean, 56 years                                                                      | Mean, 45.7 years                                            |
|                                | Median, 69 years                                                                   | Median, 56 years                                                                    | Median, 48.0 years                                          |
|                                | Range, 30.0–84.0 years                                                             | Range, 48–68 years                                                                  | Range, 1 week–84 years                                      |
| **Gender**                     | Male, 14/21 (66.6 %)                                                               | Male, 4/9 (44.4 %)                                                                  | Male, 113/173 reported (65.3 %)                             |
|                                | Female, 7/21 (33.3 %)                                                              | Female, 5/9 (55.5 %)                                                                | Female, 60/173 reported (34.7 %)                            |
|                                | Male to female ratio, 2:1                                                          | Male to female ratio, 0.8:1                                                         | Male to female ratio, 1.88:1                                |
| **% unilateral**               | 21/21 (100 %)                                                                      | 8/9 (88.9 %)                                                                         | 108/178 (60.7 %) unilateral                                |
| **Indication for corticosteroid** | RVO, 7/21 (33.3 %)                                                                | N/A                                                                                  | N/A                                                         |
|                                | DME, 8/21 (38.0 %)                                                                 | N/A                                                                                  | N/A                                                         |
|                                | Uveitic CME, 7/21 (33.3 %)                                                         | N/A                                                                                  | N/A                                                         |
|                                | CNVM due to AMD, 2/21 (9.5 %)                                                      | N/A                                                                                  | N/A                                                         |
|                                | IRIU, 0/21 (0.0 %)                                                                 | N/A                                                                                  | N/A                                                         |
| **Corticosteroid dose/route**  | 1.5–4 mg IVT, 8/21 (38.0 %)                                                       | N/A                                                                                  | N/A                                                         |
|                                | 8–20 mg, 5/21 (23.8 %)                                                            | N/A                                                                                  | N/A                                                         |
|                                | 40 mg, 2/21 (9.0 %)                                                                | N/A                                                                                  | N/A                                                         |
|                                | FA implant, 2/21 (9.0 %)                                                           | N/A                                                                                  | N/A                                                         |
|                                | Range, 1.5–40 mg                                                                  | N/A                                                                                  | N/A                                                         |
| **Time from corticosteroid dosing to retinitis (months)** | Mean, 4.3 months                                                                   | N/A                                                                                  | N/A                                                         |
|                                | Median, 4.0 months                                                                | N/A                                                                                  | N/A                                                         |
|                                | Range, 0.25–13.0 months                                                           | N/A                                                                                  | N/A                                                         |
| **Timing of CMV retinitis relative to thymoma diagnosis (months)** | N/A                                                                               | Retinitis diagnosed after thymoma, 8/9 (88.9 %)                                      | N/A                                                         |
|                                |                                                                                   | Mean, 31.4 months after thymoma                                                     | N/A                                                         |
|                                |                                                                                   | Median, 24 months after thymoma                                                     | N/A                                                         |
|                                |                                                                                   | Range, 75 months after to 1 month before                                            | N/A                                                         |
| **Associated systemic diseases** | N/A                                                                               | Respiratory infections, 7/9 (77.7 %)                                                | No underlying systemic illness, 9/178 (5.1 %)               |
|                                |                                                                                   | Non-ocular CMV, 2/9 (22.2 %)                                                        | Organ or bone marrow transplant, 61/178 (34.3 %)             |
|                                |                                                                                   | Other opportunistic infections, 3/9 (33.3 %)                                         | Autoimmune disease, 34/178 (19.1 %)                         |
|                                |                                                                                   |                                                                                     | Leukemia or lymphoma, 51/178 (28.7 %)                      |
|                                |                                                                                   |                                                                                     | Primary immune deficiency, 10/178 (5.6 %)                  |
|                                |                                                                                   |                                                                                     | Other systemic medical conditions, 24/178 (13.5 %)          |
|                                |                                                                                   |                                                                                     | N/A                                                         |
|                                |                                                                                   |                                                                                     | N/A                                                         |
| **Immunosuppressive medication** | N/A                                                                               | N/A                                                                                  | N/A                                                         |
|                                |                                                                                   |                                                                                     | No medication, 55/160 reported (34.4 %)                     |
|                                |                                                                                   |                                                                                     | Using medication, 105/160 reported (65.6 %)                 |
|                                |                                                                                   |                                                                                     | Using multiple immunosuppressive medication, 78/105 (74.3 %)| |
|                                |                                                                                   |                                                                                     | Using chemotherapy, 51/105 (48.6 %)                         |
Table 5 Summary of cases of CMV retinitis in the literature without human immunodeficiency virus infection (Continued)

| Associated autoimmune diseases |  |  |  |  |  |  |  |
|--------------------------------|---|---|---|---|---|---|---|
| N/A                            |  |  |  |  |  |  |  |
| Myasthenia gravis, 2/8 reported (25.0 %) |  |  | Using antimetabolites or leukocyte signaling inhibitors, 49/105 (46.7 %) | N/A |
| Pure red cell aplasia, 2/9 cases (22.2 %) |  |  |  |  |  |  |  |
| Associated immunologic laboratory abnormalities |  |  |  |  |  |  |  |
| N/A                            |  |  |  |  |  |  |  |
| Generalized lymphopenia: 3/5 reported (60.0 %) |  |  |  |  |  |  |  |
| Low CD3+ T cells (<672 /μL), 1/3 reported (33.3 %) |  |  |  |  |  |  |  |
| Low CD4+ T cells (<360/μL), 5/6 reported (83.3 %) |  |  |  |  |  |  |  |
| Low CD8 count (<240 /μL), 0/4 reported (0.0 %) |  |  |  |  |  |  |  |
| Low CD4+/CD8+ ratio (<0.6), 5/6 reported (83.3 %) |  |  |  |  |  |  |  |
| Low NK cells (<130 /μL), 1/2 reported (50.0 %) |  |  |  |  |  |  |  |
| Low serum IgG (<8 g/L), 7/8 reported (87.5 %) |  |  |  |  |  |  |  |
| Low serum IgM (<0.5 g/L), 7/8 reported (87.5 %) |  |  |  |  |  |  |  |
| Low serum IgA (<1.1 g/L), 8/8 reported (87.5 %) |  |  |  |  |  |  |  |
| Panhypogammaglobulinemia, 7/8 reported (87.5 %) |  |  |  |  |  |  |  |

CMV testing

| Positive aqueous or vitreous PCR, 20/21 (95.2 %) | Positive aqueous PCR, 4/9 (44.4 %) | Positive aqueous PCR, 65/131 reported (49.6 %) |
| Confirmed by other means, 1/21 (4.8 %) | Confirmed by other means, 5/9 (55.5 %) | Confirmed by other means, 29/131 reported (22.1 %) |

Zone involved

| Zone I, 4/20 reported (20.0 %) | Zone I, 5/8 reported (62.5 %) | Zone I, 72/97 eyes reported (74.2 %) |
| Zone II, 17/20 reported (85.0 %) | Zone II, 4/8 reported (50 %) | Zone II, 87/97 eyes reported (89.7 %) |
| Zone III, 1/20 reported (5.0 %) | Zone III, 2/8 reported (25 %) | Zone III, 39/97 eyes reported (40.2 %) |

Vision when retinitis was first diagnosed

| Acuity better than 20/40, 2/21 eyes (9.5 %) | Acuity better than 20/40, 0/9 eyes (0.0 %) | Acuity better than 20/40, 61/179 reported eyes (34.1 %) |
| Acuity between 20/40 and 20/200, 11/21 eyes (52.3 %) | Acuity between 20/40 and 20/200, 7/9 eyes (77.7 %) | Acuity between 20/40 and 20/200, 70/179 reported eyes (39.1 %) |
| Acuity worse than 20/200, 8/21 eyes (38.0 %) | Acuity worse than 20/200, 2/9 eyes (22.2 %) | Acuity worse than 20/200, 48/179 reported eyes (26.8 %) |

Retinitis treatment

| Intravitreal therapy alone, 5/21 (23.8 %) | Intravitreal therapy alone, 1/9 (11.1 %) | Intravitreal therapy alone, 30/126 reported (23.8 %) |
| Systemic therapy alone, 5/21 (23.8 %) | Systemic therapy alone, 2/9 (22.2 %) | Systemic therapy alone, 57/126 reported (45.2 %) |
| Intravitreal and systemic therapy, 12/21 (52.3 %) | Intravitreal and systemic therapy, 6/9 (66.6 %) | Intravitreal and systemic therapy, 39/126 reported (31.0 %) |

Follow-up (months)

| Mean = 11.8 months | Mean = 4.56 months | Mean = 14.2 months |
| Median = 5.5 months | Median = 6 months | Median = 6.0 months |
| Range = 1–84 months | Range = 1.5–7 months | Range = 0–216 months |

Vision at the last visit

| Acuity better than 20/40, 2/21 eyes (9.5 %) | Acuity better than 20/40, 0/9 eyes (0.0 %) | Acuity better than 20/40, 52/171 reported eyes (30.4 %) |
method of diagnostic confirmation of CMVR was reported in 1 of the 10 cases (10.0 %), among which the diagnosis of CMVR was confirmed serum PCR testing. The retinitis responded to antiviral therapy in all cases. The therapeutic treatment administered was reported in 6 of the 10 cases (60.0 %). Of these 6 cases, treatment was administered systemically only in 33.3 % of patients and intraocularly alone in 66.7 % patients. Visual acuity at last follow-up visit was reported in 8 patients and 13 eyes (mean 22.2 months; median 19 months; range 1 to 43 months). Visual acuity at last follow-up was better than 20/40 in 38.5 %, between 20/40 and 20/200 in 46.1 %, and worse than 20/200 in 15.4 % of eyes. Since the December, 2014, cutoff for our literature review, there have been several publications of CMVR in HIV-negative patients [108–113]. While these publications are not incorporated into this review, the clinical context in which CMVR developed and the clinical characteristics of the retinitis and the treatment(s) given for the infection were not significantly different from those previously reported or from the conclusions drawn by our review [114].

**Conclusions**

Although uncommon, CMVR can occur in the absence of HIV infection. Over 95 %, of HIV-negative patients who developed CMVR were found, ultimately, to have one or more factors contributing to a relative decline in immune function, such as advanced age, an underlying malignancy, an autoimmune disease or organ/bone transplantation requiring systemic immunosuppression, administration of periocular or intraocular corticosteroids, diabetes mellitus, or, less commonly, an inherited or acquired immune disorder, such as Good syndrome. While the clinical features of CMVR were generally similar in HIV-negative and HIV-positive patients, accumulated data regarding the rate of moderate to severe intraocular inflammation and occlusive retinal vasculitis would seem to suggest that these more ARN-like features occur more often in HIV-negative patients.

**Abbreviations**

AMD age-related macular degeneration, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CNVM cystoid macular edema, CWM choroidal neovascular membrane, DME diabetic macular edema, ERM epiretinal membrane, FA fluocinolone acetonide, IRU immune recovery uveitis, IgG immunoglobulin G, CMV cytomegalovirus, NR not reported, PCR polymerase chain reaction, CD cluster designation, NK natural killer, N/A not applicable

"Data used from paper done by Takakura et al. [89] currently in peer review "Ocular Immunology and Inflammation"

"All patients were HIV negative"

"Zone definitions are as follows: Zone I defined as macula or optic nerve involvement; Zone II defined as mid-periphery; Zone 3 defined as outer periphery. Zone definitions referenced in this paper: Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN. Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol. 2011;129(11):1507–8 [115]

"Dosing with each modality varied widely across studies"

**Additional file**

Additional file 1: Table S1. Summary of reported cases of cytomegalovirus (CMV) retinitis in immunocompetent HIV-negative patients. (DOC 497 kb)

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

KD is the primary author who was responsible for conceiving the study, the acquisition of the data, and the analysis and interpretation. He drafted the manuscript and revised it critically for content. DT and LWV were also responsible for the acquisition of the data and reading and approving the final manuscript. ETC was responsible for conceiving the study, participated in the review design, and revised the manuscript critically for content. ETC read and approved the final manuscript. All authors read and approved the final manuscript.

**Authors’ information**

Kenneth M. Downes, M.D. is a resident physician at California Pacific Medical Center. Dariusz Tarasewicz, M.D., Ph.D. is a physician at the Department of Ophthalmology at Kaiser Permanente Medical Center in South San Francisco, California. Laurie J. Weisberg, MD is a physician at the Department of Hematology/Oncology at Kaiser Permanente South San Francisco Medical Center in South San Francisco, California. Emmett T. Cunningham Jr, M.D., M.P.H., Ph.D. is a physician at the West Coast Retina Medical Group in San Francisco, California.

**Acknowledgements**

This study is supported in part by The Pacific Vision Foundation and The San Francisco Retina Foundation (ETC.).

**Author details**

1The Department of Ophthalmology, California Pacific Medical Center, 2340 Clay Street 5th, San Francisco, CA 94115, USA. 2The Department of Ophthalmology, Kaiser Permanente Medical Center, South San Francisco, CA, USA. 3The Department of Hematology/Oncology, Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA, USA. 4The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA. 5The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA. 6West Coast Retina Medical Group, San Francisco, CA, USA.

Received: 24 September 2015 Accepted: 4 January 2016
Published online: 25 January 2016

**References**

1. Liang X, Lovell MA, Capocelli KE et al (2010) Thymoma in children: report of 2 cases and review of the literature. Pediatr Dev Pathol 13(3):202–208
50. Eid AJ, Bakri SJ, Kippittayat S, Razonable RR (2008) Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 10(1):113–8, 2007 May 19

51. Gooi P, Farmer J, Hurley B, Brodbaker E (2008) Cytomegalovirus retinitis mimicking intravascular lymphoma. Clin Ophthalmol 2(4):969–71

52. Haerter G, Manfras BJ, de Jong-Hesse Y, Wilts H, Mertens T, Kern P, Schmitt M (2004) Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 39(1):88–94, 2004 Oct 11

53. Hoang QV, Simon DM, Kumar GN, Oh F, Goldstein DA (2010) Recurrent CMV retinitis in a patient with dermatomyositis. Clin Rheumatol 29(5):801–7, 2010 May

54. Larsson K, Lönnqvist B, Ringdén O, Hedquist B, Ljungman P (2002) CMV retinitis in a non-HIV patient with drug-resistant CMV. Graefes Arch Clin Exp Ophthalmol 240(5):737–40. doi:10.1007/s00417-002-0893-3, 2002 Jan

55. Kim HR, Kim SD, Kim SH, Yoon CH, Lee SH, Park SH, Kim HY (2007) Cytomegalovirus retinitis in a patient with dermatomyositis. Clin Rheumatol 26(5):801–6, 2007 May 15

56. Kobayashi R, Takahashi K, Suzuki D, Nasu T, Uetake K, Matsumoto Y (2012) Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia. Pediatr Int 54(2):288–90

57. Lafaut BA, Vianna RN, De Baets F, Meire F (1995) Unilateral cytomegalovirus retinitis in a patient with immunoglobulin G2 deficiency. Ophthalmologica 209(1):40–3

58. Larsson K, Lönqvist B, Ringdén O, Hedquist B, Ljungman P (2002) CMV retinitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 29(5):618–21

59. Lewis MA, Jaffe GJ (1996) Cytomegalovirus retinitis associated with anticoagulant syndrome. Retina 18(6):568

60. Long HM, Dick A (2005) Presumed CMV associated necrotizing retinopathy in a non-HIV immunocompromised host. Clin Exp Ophthalmol 33(3):330–2

61. Margo CE, Arangio JL (1998) Cytomegalovirus retinitis and the lupus anticoagulant syndrome. Retina 18(6):568–70

62. Masi MA, Jaffe GJ (1996) Cytomegalovirus retinitis associated with Hodgkin’s disease. Retina 16(4):324–7

63. Nasir MA, Jaffe GJ (1996) Cytomegalovirus retinitis associated with normal CD4(+) counts. Eye (Lond) 20(5):618

64. Raz J, Aker M, Engeland D, Ramu N, Or R, Cohen E, Nagler A, Benezra D (2003) Cytomegalovirus retinitis in a patient with normal lymphocyte count who had undergone multiple ocular surgeries in an immunocompetent patient. Case Rep Ophthal 3(3):356–9. doi:10.1159/000343705, 2010 Oct 23

65. Tuncer S, Oray M, Yildirim Y, Cangiloglu Y, Tugal-Tutkun I. Bilateral intraocular calcification in necrotizing cytomegalovirus retinitis. Int Ophthalmol. 2014.

66. Tzalla C, Decembrino L, Di Comite A, Bollani L, Colombo R, Stronati M (2010) Colonic stricture and retinitis due to cytomegalovirus infection in an immunocompetent patient. Pediatr Int 52(4):659–60

67. Welling JD, Tarabishy AB, Christoforidis JB (2012) Cytomegalovirus retinitis mimicking intraocular lymphoma. Clin Ophthalmol 2(4):961–5. doi:10.2147/OPTH.S31130, 2012 Sep 20

68. Oschner A, Murthy V, Kollipara R, Kenneth Lord R, Olulu O (2013) Intravitreal ganciolvir for neonatal cytomegalovirus-associated retinitis: a case report. J Perinatol 33(4):329–31. doi:10.1038/jp.2012.139

69. Patel MP, Kute VB, Gumber MR, Shah PR, Patel HV, Dhananjay KL, Jain SH, Trivedi HL, Vanek AV (2013) Successful treatment of Nocardia pneumonia with cytomegalovirus retinitis coinfection in a renal transplant recipient. Int Urol Nephrol 45(2):581–5

70. Piersigilli F, Catena G, De Gasperi MR, Lozzi S, Auriol C (2012) Active retinitis in an infant with postnatally acquired cytomegalovirus infection. J Perinatol 32(11):559–62. doi:10.1038/jp.2011.142

71. Teh BK, Khot AS, Harrison SJ, Prince HM, Slavin MA (2013) A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. Transplant Infect Dis 15(4):E134–8. doi:10.1111/tid.12106, 2013 Jun 29

72. Tontiyama K, Suzuki T, Hara Y, Ohashi Y (2012) Cytomegalovirus retinitis after multiple ocular surgeries in an immunocompetent patient. Case Rep Ophthal 3(3):356–9. doi:10.1159/000343705, 2012 Oct 23

73. Tuncer S, Oray M, Yildirim Y, Cangiloglu Y, Tugal-Tutkun I. Bilateral intraocular calcification in necrotizing cytomegalovirus retinitis. Int Ophthalmol. 2014.

74. Iwanaga M, Zaitsu M, Ishii E, Nishimura Y, Inada S, Yoshiki H, Okinami S, Downes AM, Jorma M, et al. (2013) Cytomegalovirus Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature. Ocular Immunol & Inflammation. 2014, 1–8.

75. Babiuch AS, Ravage ZB, Merrill PT (2010) Cytomegalovirus Acute Retinal Necrosis in an Immunocompetent Patient. Am J Ophthalmol. 150(6):1141–1143

76. Deflyer M-N, Rougier M-B, Hubschman J-P, Aouizérate F, Korobelnik J-F (2010) Cytomegalovirus retinitis after intravitreal triamcinolone injection in a patient with central retinal vein occlusion. Eur J Ophthalmol 20(5):414–6

77. Piersigilli F, Catena G, De Gasperi MR, Lozzi S, Auriol C (2012) Active retinitis in an infant with postnatally acquired cytomegalovirus infection. J Perinatol 32(11):559–62. doi:10.1038/jp.2011.142

78. Tontiyama K, Suzuki T, Hara Y, Ohashi Y (2012) Cytomegalovirus retinitis after multiple ocular surgeries in an immunocompetent patient. Case Rep Ophthal 3(3):356–9. doi:10.1159/000343705, 2012 Oct 23

79. Tuncer S, Oray M, Yildirim Y, Cangiloglu Y, Tugal-Tutkun I. Bilateral intraocular calcification in necrotizing cytomegalovirus retinitis. Int Ophthalmol. 2014.

80. Delyfer M-N, Rougier M-B, Hubschman J-P, Aouizérate F, Korobelnik J-F (2010) Cytomegalovirus Acute Retinal Necrosis in an Immunocompetent Patient. Am J Ophthalmol. 150(6):1141–1143

81. Saded M, Bereren J, Margolis T (2005) Cytomegalovirus Retinitis After Intravitreal Triamcinolone in an Immunocompetent Patient. Am J Ophthalmol. 140(6):1141–1143

82. Deflyer M-N, Rougier M-B, Hubschman J-P, Aouizérate F, Korobelnik J-F (2010) Cytomegalovirus retinitis after intravitreal triamcinolone injection in a patient with central retinal vein occlusion. Eur J Ophthalmol 20(5):414–6

83. Iwanaga M, Zaitsu M, Ishii E, Nishimura Y, Inada S, Yoshiki H, Okinami S, Downes AM, Jorma M, et al. (2013) Cytomegalovirus Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature. Ocular Immunol & Inflammation. 2014, 1–8.

84. Sekiryu T, Iida T, Kaneko H, Saito M (2008) Cytomegalovirus retinitis after intravitreal triamcinolone injection in an immunocompetent patient. Jpn J Ophthalmol 52(5):414–6

85. Iwanaga M, Zaitsu M, Ishii E, Nishimura Y, Inada S, Yoshiki H, Okinami S, Downes AM, Jorma M, et al. (2013) Cytomegalovirus Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature. Ocular Immunol & Inflammation. 2014, 1–8.

86. Iwanaga M, Zaitsu M, Ishii E, Nishimura Y, Inada S, Yoshiki H, Okinami S, Downes AM, Jorma M, et al. (2013) Cytomegalovirus Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature. Ocular Immunol & Inflammation. 2014, 1–8.
96. Shah AM, Oster SF, Freeman WR (2010) Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am J Ophthalmol 149(3):433–40
97. Toyokawa N, Kimura H, Kuroda S (2010) Cytomegalovirus Retinitis After Subtenon TA and Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in an Immunocompetent Patient with Age-Related Macular Degeneration and Diabetes Mellitus. Jpn J Ophthalmol 54(2):166–8
98. Tugal-Tutkun I, Arar B, Cagatay A (2010) CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behçet’s uveitis. International Ophthalmology 30(5):591–3
99. Vertes D, Snyers B, De Potter P (2010) Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids. International Ophthalmology 30(5):595–7
100. Zaborowski AG. Cytomegalovirus Retinitis Following Intravitreal Triamcinolone Acetonide in a Patient with Chronic Uveitis on Systemic Immunosuppression. Ocular immunology and inflammation. 2013;(October):1–2
101. Jabs DA (1995) Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 93:623–83
102. Jabs DA et al (2007) Longitudinal Study of the Ocular Complications of AIDS 1. Ocular Diagnoses at Enrollment. Ophthalmology 114:4
103. Jabs DA et al (2007) Longitudinal Study of the Ocular Complications of AIDS 2. Ocular Examination Results at Enrollment. Ophthalmology 114:4
104. Jabs DA (2011) Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome—Bench to Bedside: LXVII Edward Jackson Memorial Lecture. American journal of ophthalmology 151:2
105. Jabs DA et al (2010) Course of Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy: Five-year Outcomes. Ophthalmology 117(11):2152–2161
106. Urban, B. Et al. Immune Recovery Uveitis: Pathogenesis, Clinical Symptoms, and Treatment. Mediators of Inflammation Volume 2014, Article ID 971417.
107. Ruiz Cruz, M, et al. Proposed Clinical Case Definition for Cytomegalovirus–Immune Recovery Retinitis. HIV/AIDS CID 2014:59 (15 July)
108. Vishnevskia-Dai V, Shapiro Y, Rahav G, Shimon I, Somech R, Moisseiev J (2015) Cytomegalovirus retinitis in HIV-negative patients: a practical management approach. Ophthalmology 122(4):866–868
109. Miszewska-Szyszkowska D, Mikolajczyk N, Komuda-Leszek E, Wleczkowska R, Swider R, Debonis-Matekowska D, Szmidt J, Durlik M (2015) Severe cytomegalovirus infection in second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi organ failure with fatal outcome: a case report. Ann Transplant 20:169–74
110. Chan TS, Cheung CY, Yeung IY, Hwang YY, Gill H, Wong IY, Kwong YL (2015) Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine. Ann Hematol 94(6):1043–7
111. Vannozzi L, Bacherini D, Sodi A, Beccastrini E, Emmi G, Giorni A (2015) Menchini U. Cytomegalovirus retinitis following intravitreal dexamethasone implant in a patient with central retinal vein occlusion, Acta Ophthalmol 112. Matsumoto A, Umeda K, Kawa K, Maeda S, Kinehara T, Saida S, Kato L, Hirai H, Watanabe K, Yasumi T, Heike T, Tsujikawa A, Uji A, Usami I, Ito K, Adachi S (2015) Development of CMV retinitis in an antigenemia-negative infant after cord blood transplantation. Rinsho Ketsueki 56(5):506–10
112. Jeon S, Lee WK (2015) Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-negative Cohort: Long-term Management and Complications. Ocul Immunol Inflamm 11:1–8
113. Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN (2011) Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol 129(11):1507–8